Trade Names:Iodotope- Capsules 1 to 50 mCi- Oral Solution 7.05 mCi
Trade Names:Sodium Iodide I 131- Capsules 0.75 to 100 mCi- Oral Solution 3.5 to 150 mCi
After rapid GI absorption, iodine 131 is primarily distributed within extracellular fluid. It is trapped and rapidly converted to protein-bound iodine by the thyroid; it is concentrated, but not protein bound, by the stomach and salivary glands. It is promptly excreted by kidneys. About 90% of the local irradiation is caused by beta radiation and 10% is caused by gamma radiation. Iodine 131 has a physical half-life of 8.04 days.
Thyroid carcinoma, hyperthyroidism.
Preexisting vomiting and diarrhea; women who are or may become pregnant.
PO Individualize dosage. Usual dose for ablation of normal thyroid tissue: 50 mCi, with subsequent therapeutic doses usually 100 to 150 mCi.
Store in transport container until time of administration.
Uptake of iodine 131 will be affected by recent intake of stable iodine in any form, or by use of thyroid, antithyroid, and certain other drugs.
None well documented.
Acute thyroid crises.
Depression of hematopoietic system with large doses; bone marrow depression; acute leukemia; anemia; blood dyscrasia; leukopenia; thrombocytopenia; death.
Radiation sickness; severe sialoadenitis; increased clinical symptoms; chest pain; tachycardia; rash; hives; chromosomal abnormalities; tenderness and swelling of neck; pain on swallowing; sore throat and cough may occur around third day after treatment; temporary hair thinning (may occur 2 to 3 mo after treatment).
Category X .
Discontinue breast-feeding during therapy. Do not resume breast-feeding until all radiation is absent from breast milk (approximately 14 days).
Safety and efficacy have not been established.
Contains sulfites that may cause allergic-type reactions, including anaphylactic symptoms.
Ensure minimum radiation exposure to patients and occupational workers consistent with proper patient management.
Copyright © 2009 Wolters Kluwer Health.